Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis

CNS Drugs

Volumn 30, Issue 1, 2016, Pages 41-51

  Chan, Andrew ^a   De Seze, Jérôme ^b   Comabella, Manuel ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GADOLINIUM; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; TERIFLUNOMIDE; CROTONIC ACID DERIVATIVE; TOLUIDINE DERIVATIVE;

ABDOMINAL PAIN; ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT DISORDER; BRONCHITIS; CARPAL TUNNEL SYNDROME; CYSTITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROENTERITIS; HUMAN; HYPERTENSION; INFLUENZA; LARYNGITIS; LEUKOCYTE COUNT; MENORRHAGIA; MOUTH INFECTION; MULTIPLE SCLEROSIS; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PARESTHESIA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; POLLAKISURIA; PRESCRIPTION; PRIORITY JOURNAL; RASH; RELAPSE; SCIATICA; SIDE EFFECT; SINUSITIS; TINEA PEDIS; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING; WEIGHT REDUCTION; DRUG ADMINISTRATION; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CLINICAL TRIALS, PHASE III AS TOPIC; CROTONATES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOLUIDINES; TREATMENT OUTCOME;

EID: 84956581702     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0299-y     Document Type: Article

References (23)

1. European Medicines Agency. Aubagio EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002514/WC500148682.pdf. Accessed 20 May 2015.
2. European Medicines Agency. Gilenya EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002202/WC500104528.pdf. Accessed 20 May 2015.
3. European Medicines Agency. Tecfidera EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002601/WC500162069.pdf. Accessed 12 Oct 2015.
4. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74:659-74.
5. Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther. 1995;272:460-8.
6. Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia. 2008;22:635-8.
7. Li L, Liu J, Delohery T, Zhang D, Arendt C, Jones C. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol. 2013;265:82-90.
8. Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013;81:552-8.
9. Bar-Or A, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol Neuroinflamm. 2015;2:e70. doi: 10.1212/NXI.0000000000000070.
10. European Medicines Agency. Arava EU summary of product characteristics. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000235/WC500026289.pdf. Accessed 12 Oct 2015.
11. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293-303.
12. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247-56.
13. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977-86.
14. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos LK, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20:705-16.
15. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin F, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-7.
16. European Medicines Agency. Aubagio assessment report. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002514/WC500148684.pdf. Accessed 12 Oct 2015.
17. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58:840-6.
18. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894-900.
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
20. FDA. Teriflunomide (Aubagio) prescribing information. 2014. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm423101.htm. Accessed 12 Oct 2015.
21. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62:1494-503.
22. Wiese MD, Schnabl M, O'Doherty C, Spargo LD, Sorich M, Cleland LG, et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14:R163.
23. Poser CM, Paty DW, Scheinberg L, McDonald I, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-31.